Results from phase III clinical trials with radachlorine for photodynamic therapy of pre-cancer and early cancer of cervix

Biomedical Photonics

L. G. Serova¹  V. I. Ivanova-Radkevich²  E. V. Filonenko² 

[1] Первый Московский государственный медицинский университет им. И.М. Сеченова, Москва, Россия;Национальный медицинский исследовательский радиологический центр Минздрава России, Москва, Россия;

关键词: рак шейки матки;    фотосенсибилизатор радахлорин;    фотодинамическая терапия;   

DOI  :  

来源: DOAJ

【 摘 要 】

The results of clinical study for efficacy of photodynamic therapy (PDT) with radachlorine in patients with pre-cancer and cancer of cervix are represented. The study enrolled 30 patients including 4 patients with cervical erosion, 5 patients with cervical intraepithelial neoplasia II, 13 patients with cervical intraepithelial neoplasia III, 4 patients with carcinoma in situ and 4 patients with cervical cancer stage Ia. Radachlorine was administrated as single 30 minute intravenous injection at dose of 1,0 mg/kg of body weight 3 h before irradiation (wavelength of 662 nm, light dose of 300–350 J/cm2). The results of treatment in 26 (86,7%) patients was assessed as complete tumor regression and in 4 (13,3%) patients — as partial regression. In cervical erosion, intraepithelial neoplasia II and carcinoma in situ groups total regression was in all cases. In the cervical intraepithelial neoplasia III group total regression after first course of PDT was achieved in 77% of patients, in cervical cancer stage Ia group – in 75% of patients. From 3 to 6 months after first course of treatment all patients with partial tumor regression underwent the second course of PDT with complete regression. There were no side-effects due to radachorine or PDT in the course of treatment and during follow-up. Thus, PDT with Russian photosensitizer radachlorine showed high efficiency for treatment of pre-cancer and cancer of cervix.

 

【 授权许可】

Unknown